Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
Natera and Guardant are about to shake things up with indication-specific blood tests, but Exact is keeping faith with Cologuard – for now.
Big-cap device makers on European exchanges did nicely in 2021, whereas their US-listed brethren had a harder time.
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
The quest for the Grail is beset with challenges.